First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.
Toshio ShimizuYutaka FujiwaraKan YonemoriTakafumi KoyamaJun SatoKenji TamuraAkihiko ShimomuraHiroki IkezawaMaiko NomotoKeiji FuruuchiRyo NakajimaTakuma MiuraNoboru YamamotoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The MTD of MORAb-202 was not reached. MORAb-202 demonstrated promising antitumor activity in FRα-positive solid tumors and was generally well-tolerated at the tested doses. Further investigations are required to establish appropriate dosage and clinical utility of MORAb-202.